Professional paper - Letter to the editor
SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?
British Journal of Clinical Pharmacology, 87 (2021), 11; 4476-4478. https://doi.org/10.1111/bcp.14849

Bošković, Marko; Migo, William; Likić, Robert

Linked objects
COVID-19 | Virtual collection
Cite this document

Bošković, M., Migo, W. & Likić, R. (2021). SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?. British Journal of Clinical Pharmacology, 87. (11), 4476-4478. doi: 10.1111/bcp.14849

Bošković, Marko, et al. "SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?." British Journal of Clinical Pharmacology, vol. 87, no. 11, 2021, pp. 4476-4478. https://doi.org/10.1111/bcp.14849

Bošković, Marko, William Migo and Robert Likić. "SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?." British Journal of Clinical Pharmacology 87, no. 11 (2021): 4476-4478. https://doi.org/10.1111/bcp.14849

Bošković, M., Migo, W. and Likić, R. (2021) 'SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?', British Journal of Clinical Pharmacology, 87(11), pp. 4476-4478. doi: 10.1111/bcp.14849

Bošković M, Migo W, Likić R. SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?. British Journal of Clinical Pharmacology [Internet]. 2021 November [cited 2024 October 08];87(11):4476-4478. doi: 10.1111/bcp.14849

M. Bošković, W. Migo and R. Likić, "SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?", British Journal of Clinical Pharmacology, vol. 87, no. 11, pp. 4476-4478, November 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:329087. [Accessed: 08 October 2024]

Please login to the repository to save this object to your list.